| Copyright @ www.mycsg.in |
¨ Obs |
· VERSION |
· DOMAIN |
¨ SEQUENCE |
· VARIABLE |
· LABEL |
· TYPE |
· CT_OR_FORMAT |
· ROLE |
· CDISC_NOTES |
· CORE |
· CLASS |
· VARIABLE_WO_PREFIX |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | SDTMIG 3.4 (Public Review) | TS | 1 | STUDYID | Study Identifier | Char | Identifier | Unique identifier for a study. | Req | Trial Design | STUDYID | |
| 2 | SDTMIG 3.4 (Public Review) | TS | 2 | DOMAIN | Domain Abbreviation | Char | TS | Identifier | Two-character abbreviation for the domain. | Req | Trial Design | DOMAIN |
| 3 | SDTMIG 3.4 (Public Review) | TS | 3 | TSSEQ | Sequence Number | Num | Identifier | Sequence number given to ensure uniqueness within a dataset. Allows inclusion of multiple records for the same TSPARMCD. | Req | Trial Design | SEQ | |
| 4 | SDTMIG 3.4 (Public Review) | TS | 4 | TSGRPID | Group ID | Char | Identifier | Used to tie together a group of related records. | Perm | Trial Design | GRPID | |
| 5 | SDTMIG 3.4 (Public Review) | TS | 5 | TSPARMCD | Trial Summary Parameter Short Name | Char | (TSPARMCD) | Topic | TSPARMCD (the companion to TSPARM) is limited to 8 characters and does not have special character restrictions. These values should be short for ease of use in programming, but it is not expected that TSPARMCD will need to serve as variable names. Examples: "AGEMIN", "AGEMAX". | Req | Trial Design | PARMCD |
| 6 | SDTMIG 3.4 (Public Review) | TS | 6 | TSPARM | Trial Summary Parameter | Char | (TSPARM) | Synonym Qualifier | Term for the Trial Summary Parameter. The value in TSPARM cannot be longer than 40 characters. Examples: "Planned Minimum Age of Subjects", "Planned Maximum Age of Subjects". | Req | Trial Design | PARM |
| 7 | SDTMIG 3.4 (Public Review) | TS | 7 | TSVAL | Parameter Value | Char | Result Qualifier | Value of TSPARM. Example: "ASTHMA" when TSPARM value is "Trial Indication". TSVAL can only be null when TSVALNF is populated. Text over 200 characters can be added to additional columns TSVAL1-TSVALn. See Assumption 8. | Exp | Trial Design | VAL | |
| 8 | SDTMIG 3.4 (Public Review) | TS | 8 | TSVALNF | Parameter Null Flavor | Char | ISO 21090 NullFlavor Enumeration | Result Qualifier | Null flavor for the value of TSPARM, to be populated if and only if TSVAL is null. | Perm | Trial Design | VALNF |
| 9 | SDTMIG 3.4 (Public Review) | TS | 9 | TSVALCD | Parameter Value Code | Char | Result Qualifier | This is the code of the term in TSVAL. For example, "6CW7F3G59X" is the code for Gabapentin; "C49488" is the code for Y. The length of this variable can be longer than 8 to accommodate the length of the external terminology. | Exp | Trial Design | VALCD | |
| 10 | SDTMIG 3.4 (Public Review) | TS | 10 | TSVCDREF | Name of the Reference Terminology | Char | (DICTNAM) | Result Qualifier | The name of the Reference Terminology from which TSVALCD is taken. For example; CDISC CT, SNOMED, ISO 8601". | Exp | Trial Design | VCDREF |
| 11 | SDTMIG 3.4 (Public Review) | TS | 11 | TSVCDVER | Version of the Reference Terminology | Char | Result Qualifier | The version number of the Reference Terminology, if applicable. | Exp | Trial Design | VCDVER |
| Copyright @ www.mycsg.in |
¨ Obs |
· CODELIST_VERSION |
· CODELIST_ABBREVIATION |
· CDISC_SUBMISSION_VALUE |
· APPLICABLE |
· CRF_VALUE |
¨ NUMERIC_VALUE |
· TFL_VALUE |
· CODELIST_CODE |
· CODELIST_NAME |
· CODELIST_EXTENSIBLE |
· NCI_CODELIST_LABEL |
· CDISC_DEFINITION |
· CDISC_SYNONYM_S_ |
· CODE |
· NCI_PREFERRED_TERM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | . | ||||||||||||||
| 2 | 2020-03-27 | DICTNAM | CDISC CT | . | C66788 | Dictionary Name | Yes | CDISC Dictionary Name Terminology | A standard terminology developed and maintained by Clinical Data Interchange Standards Consortium (CDISC) and the National Cancer Institute Enterprise Vocabulary Services (NCI-EVS) to support CDISC models, domains and specifications for data representation in regulated research. | CDISC Controlled Terminology; Clinical Data Interchange Standards Consortium Controlled Terminology | C163415 | Clinical Data Interchange Standards Consortium Controlled Terminology | |||
| 3 | 2020-03-27 | DICTNAM | COSTART | . | C66788 | Dictionary Name | Yes | CDISC Dictionary Name Terminology | A terminology developed and used by the Food and Drug Administration (FDA) for the coding, filing and retrieving of post marketing adverse reaction reports. (NCI) | Coding Symbols for a Thesaurus of Adverse Reaction Terms | C49471 | Thesaurus of Adverse Reaction Term Coding Symbols | |||
| 4 | 2020-03-27 | DICTNAM | CTCAE | . | C66788 | Dictionary Name | Yes | CDISC Dictionary Name Terminology | A standard terminology developed and maintained by the National Cancer Institute to report adverse events occurring in clinical trials. The CTCAE contains a grading scale for each adverse event term representing the severity of the event. | Common Terminology Criteria for Adverse Events | C49704 | Common Terminology Criteria for Adverse Events | |||
| 5 | 2020-03-27 | DICTNAM | D-U-N-S NUMBER | . | C66788 | Dictionary Name | Yes | CDISC Dictionary Name Terminology | A proprietary system developed and regulated by Dun & Bradstreet that assigns a unique nine digit numeric identifier to a single business entity location. | DUNS Numbers; Data Universal Number System | C134003 | Data Universal Numbering System | |||
| 6 | 2020-03-27 | DICTNAM | ICD | . | C66788 | Dictionary Name | Yes | CDISC Dictionary Name Terminology | A system of categories to which morbid entries are assigned according to established criteria. Included is the entire range of conditions in a manageable number of categories, grouped to facilitate mortality reporting. It is produced by the World Health Organization (from ICD-10, p1). The Clinical Modifications, produced by the United States Dept. of Health and Human Services, are larger extensions used for morbidity and general epidemiological purposes, primarily in the U.S. (MSH2005_2004_10_12) | International Classification of Diseases | C49474 | International Classification of Diseases | |||
| 7 | 2020-03-27 | DICTNAM | LOINC | . | C66788 | Dictionary Name | Yes | CDISC Dictionary Name Terminology | Published by The Regenstrief Institute, the Logical Observation Identifiers Names and Codes covers clinical and clinical laboratory terminology. (NCI) | Logical Observation Identifiers Names and Codes | C49476 | Logical Observation Identifiers Names and Codes | |||
| 8 | 2020-03-27 | DICTNAM | MED-RT | . | C66788 | Dictionary Name | Yes | CDISC Dictionary Name Terminology | A standard terminology developed and maintained by the Veterans Health Administration (VHA) that includes terminology to support the mechanism of action, physiologic effect, and asserted pharmacologic classification relationships of medications. MED-RT incorporates terminology from RxNORM, MeSH, and SNOMED CT. | Medication Reference Terminology; NDF-RT | C163416 | Medication Reference Terminology | |||
| 9 | 2020-03-27 | DICTNAM | MedDRA | . | C66788 | Dictionary Name | Yes | CDISC Dictionary Name Terminology | MedDRA is an international medical terminology designed to support the classification, retrieval, presentation, and communication of medical information throughout the medical product regulatory cycle. MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The MedDRA Maintenance and Support Services Organization (MSSO) holds a contract with the International Federation of Pharmaceutical Manufacturers Associations (IFPMA) to maintain and support the implementation of the terminology. (NCI) | Medical Dictionary for Regulatory Activities | C43820 | MedDRA | |||
| 10 | 2020-03-27 | DICTNAM | SNOMED | . | C66788 | Dictionary Name | Yes | CDISC Dictionary Name Terminology | A multiaxial, hierarchical classification system for diseases in man developed by the College of American Pathologists. (NCI) | Systematized Nomenclature of Medicine | C53489 | Systematized Nomenclature of Medicine | |||
| 11 | 2020-03-27 | DICTNAM | UNII | . | C66788 | Dictionary Name | Yes | CDISC Dictionary Name Terminology | A standard terminology developed and maintained by the Department of Veterans Affairs/Veterans Health Administration designated federal collaborative Structured Product Labeling Interagency Expert Panel (SPLIEP). It contains terminology to support the mechanism of action, physiologic effect, and asserted pharmacologic classification relationships of drug ingredients and food allergens. | SRS-UNII; Substance Registration System-Unique Ingredient Identifier | C163417 | Substance Registration System-Unique Ingredient Identifier | |||
| 12 | 2020-03-27 | DICTNAM | WHO ATC CLASSIFICATION SYSTEM | . | C66788 | Dictionary Name | Yes | CDISC Dictionary Name Terminology | A World Health Organization (WHO) classification system, developed and maintained by the WHO Collaborating Centre for Drug Statistics Methodology, for medicinal substances where active substances are divided into different groups according to the organ or system on which they act and their therapeutic, pharmacological, and chemical properties. | Anatomical Therapeutic Chemical Classification System | C154331 | Anatomical Therapeutic Chemical Classification System | |||
| 13 | 2020-03-27 | DICTNAM | WHOART | . | C66788 | Dictionary Name | Yes | CDISC Dictionary Name Terminology | A terminology implemented by the World Health Organization to describe adverse reactions to a prescribed medication or treatment regimen. (NCI) | World Health Organization Adverse Reaction Terms | C49468 | World Health Organization Adverse Reaction Terminology | |||
| 14 | 2020-03-27 | DICTNAM | WHODD | . | C66788 | Dictionary Name | Yes | CDISC Dictionary Name Terminology | A reference source of drugs and drug associated information maintained by the World Health Organization. (NCI) | WHODrug Global; World Health Organization Drug Dictionary | C49475 | World Health Organization Drug Dictionary | |||
| 15 | 2020-03-27 | TSPARM | Actual Number of Subjects | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | Actual number of subjects enrolled; may include subjects who were not randomized. | Actual Number of Subjects | C98703 | Actual Subject Number | |||
| 16 | 2020-03-27 | TSPARM | Adaptive Design | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | Indicate if the study includes a prospectively planned opportunity for modification of one or more specified aspects of the study design and hypotheses based on analysis of data (usually interim data) from subjects in the study. | Adaptive Design | C146995 | Adaptive Study Design Indicator | |||
| 17 | 2020-03-27 | TSPARM | Added on to Existing Treatments | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The addition of a therapeutic product to the existing regimen in a clinical trial, where both entities remain as discrete products. | Added on to Existing Treatments | C49703 | Test Product Added to Existing Treatment | |||
| 18 | 2020-03-27 | TSPARM | Additional Outcome Measure | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | Additional key measures that will be used to evaluate the intervention(s) or, for observational studies, that are a focus of the study. These are the outcome measures not used to assess primary or secondary objectives. | Additional Outcome Measure | C156601 | Additional Outcome Measure | |||
| 19 | 2020-03-27 | TSPARM | Biospecimen Retention Contains DNA | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | A textual description as to whether a biospecimen is retained and/or contains DNA. | Biospecimen Retention Contains DNA | C126058 | Biospecimen Retained and/or Contains DNA Indicator | |||
| 20 | 2020-03-27 | TSPARM | CDISC Therapeutic Area User Guide | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The name and version of the CDISC therapeutic area user guide that is being used in the study submission. | CDISC Therapeutic Area User Guide | C156602 | CDISC Therapeutic Area User Guide Name and Version | |||
| 21 | 2020-03-27 | TSPARM | Citation Used in Study | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | A bibliographical reference related to a particular study. | Citation Used in Study | C127788 | Clinical Study Citation | |||
| 22 | 2020-03-27 | TSPARM | Clinical Study Report Archive Date | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The date when the clinical study report was archived. | Clinical Study Report Archive Date | C139273 | Clinical Study Report Archive Date | |||
| 23 | 2020-03-27 | TSPARM | Clinical Study Sponsor | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | An entity that is responsible for the initiation, management, and/or financing of a clinical study. | Clinical Study Sponsor; Sponsor; Study Sponsor | C70793 | Clinical Study Sponsor | |||
| 24 | 2020-03-27 | TSPARM | Commercial Sponsor Status | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The state or condition of the sponsor as pertains to whether the sponsor is considered a commercial entity. | Commercial Sponsor Status | C127789 | Sponsor Commercial Status | |||
| 25 | 2020-03-27 | TSPARM | Comparative Treatment Name | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | A therapeutically active agent that is intended to provide reference measurements for the experimental protocol of a clinical trial. | Comparative Treatment Name | C68612 | Active Comparator Drug | |||
| 26 | 2020-03-27 | TSPARM | Confirmed Response Minimum Duration | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The protocol specified minimum amount of time needed to meet the definition of a confirmed response to treatment. | Confirmed Response Minimum Duration | C98715 | Confirmed Response Minimum Duration | |||
| 27 | 2020-03-27 | TSPARM | Control Type | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | Comparator against which the study treatment is evaluated. | Control Type | C49647 | Control Type | |||
| 28 | 2020-03-27 | TSPARM | Country of Manufacture | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The name of the country within which the final product under study is produced. | Country of Manufacture | C124455 | Country of Manufacture | |||
| 29 | 2020-03-27 | TSPARM | Current Therapy or Treatment | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The literal identifier of the therapy or medication that is currently being given per protocol. | Current Therapy or Treatment | C85582 | Current Therapy | |||
| 30 | 2020-03-27 | TSPARM | Data Cutoff Date | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | A date which indicates any data collected by this date will be used for analysis. | Data Cutoff Date | C98717 | Data Cutoff Date | |||
| 31 | 2020-03-27 | TSPARM | Data Cutoff Description | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | Text that describes the cutoff date. | Data Cutoff Description | C98718 | Data Cutoff Date Description | |||
| 32 | 2020-03-27 | TSPARM | Data Monitoring Committee Indicator | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | An indication as to whether the clinical trial has an appointed data monitoring committee. | Data Monitoring Committee Indicator | C127790 | Data Monitoring Committee Indicator | |||
| 33 | 2020-03-27 | TSPARM | Delayed Graft Function Dx Criteria | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | A standard by which the determination of delayed graft function (DGF) is established. | Delayed Graft Function Diagnostic Criteria; Delayed Graft Function Dx Criteria | C135514 | Delayed Graft Function Diagnostic Criteria Name | |||
| 34 | 2020-03-27 | TSPARM | Diagnosis Group | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | A grouping of individuals on the basis of a shared procedure or disease, or lack thereof. | Diagnosis Group | C49650 | Diagnosis Group | |||
| 35 | 2020-03-27 | TSPARM | Diagnostic Criteria | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | A standard from which a judgment concerning a medical diagnosis can be established. | Diagnostic Criteria | C117960 | Diagnostic Criteria | |||
| 36 | 2020-03-27 | TSPARM | Dose Form | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The pharmaceutical dosage form of the drug administered. | Dose Form | C42636 | Pharmaceutical Dosage Form | |||
| 37 | 2020-03-27 | TSPARM | Dose Regimen | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The planned schedule for the administration of an agent (such as a drug, substance or radiation). | Dose Regimen | C71137 | Dose Regimen | |||
| 38 | 2020-03-27 | TSPARM | Dose Units | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The unit of measure for the dosage form. | Dose Units | C73558 | Dosage Form Unit | |||
| 39 | 2020-03-27 | TSPARM | Dose per Administration | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The amount of drug administered to a patient or test subject at one time or the total quantity administered. [AMA Manual of Style] (CDISC Glossary) | Dose Level; Dose per Administration | C25488 | Dose | |||
| 40 | 2020-03-27 | TSPARM | Dosing Frequency | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The number of doses administered per a specific interval. | Dosing Frequency | C89081 | Dose Frequency | |||
| 41 | 2020-03-27 | TSPARM | ECG Continuous Monitoring | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | Indicates whether the 10-second ECGs for this study were extracted from a continuous recording. | ECG Continuous Monitoring | C119561 | ECG Continuous Monitoring Indicator | |||
| 42 | 2020-03-27 | TSPARM | ECG Planned Primary Lead | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The ECG lead which was planned to be used for ECG interval measurements for this study. | ECG Planned Primary Lead | C119562 | ECG Planned Primary Lead for Study | |||
| 43 | 2020-03-27 | TSPARM | ECG Read Method | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The degree of automation involved in assessing the ECGs for this study. | ECG Read Method | C119564 | ECG Read Method Degree of Automation | |||
| 44 | 2020-03-27 | TSPARM | ECG Reading Blinded | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | Indicates whether assessors of ECGs for this study were blinded to subject identity, timing and treatment. | ECG Reading Blinded | C119560 | ECG Evaluator Blinding Parameters | |||
| 45 | 2020-03-27 | TSPARM | ECG Replicates On-Treatment | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | Indicates whether this study includes replicate ECGs for time points during the on-treatment portion of the study. | ECG Replicates On-Treatment | C119566 | ECG Replicates On-Treatment Indicator | |||
| 46 | 2020-03-27 | TSPARM | ECG Replicates at Baseline | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | Indicates whether this study includes replicate ECGs for time points during the baseline portion of the study. | ECG Replicates at Baseline | C119565 | ECG Replicates at Baseline Indicator | |||
| 47 | 2020-03-27 | TSPARM | ECG Twave Algorithm | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The algorithm used to identify the end of the T wave for ECGs for this study. | ECG Twave Algorithm | C119582 | ECG T Wave Algorithm | |||
| 48 | 2020-03-27 | TSPARM | ECG Used Same Lead | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | Indicates whether all ECG interval measurements for the study were based on the same lead. | ECG Used Same Lead | C119563 | ECG Used Same Lead Indicator | |||
| 49 | 2020-03-27 | TSPARM | EMA Decision Number for PIP | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | An alphanumeric code assigned by the European Medicines Agency (EMA) to an EMA regulatory decision for a pediatric investigation plan (PIP). | EMA Decision Number for PIP | C126059 | EMA Decision Number for Pediatric Investigation Plan | |||
| 50 | 2020-03-27 | TSPARM | Email Address for XML File | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The Email address to which copies of the XML format of the EudraCT application should be sent. | Email Address for XML File | C127791 | E-mail Address for XML File Feedback | |||
| 51 | 2020-03-27 | TSPARM | EudraCT Resubmission Indicator | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | An indication as to whether the trial being submitted to the EudraCT is a trial that has been previously submitted to the EudraCT system. | EudraCT Resubmission Indicator | C126060 | EudraCT Resubmission Indicator | |||
| 52 | 2020-03-27 | TSPARM | EudraVigilance Sender ID | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | A unique identifier assigned to the organization that is transmitting an adverse drug reaction report to the EudraVigilance system. | EudraVigilance Sender ID | C126061 | EudraVigilance Sender Identifier | |||
| 53 | 2020-03-27 | TSPARM | EudraVigilance Sender Organization | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The name of the group or institution that is transmitting an adverse drug reaction report to the EudraVigilance system. | EudraVigilance Sender Organization | C126090 | EudraVigilance Sender Organization | |||
| 54 | 2020-03-27 | TSPARM | Expanded Access Record NCT Number | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The unique alphanumeric identifier for the study with associated expanded access record, as assigned by the clinicaltrials.gov protocol registration and results system (PRS). | Expanded Access Record NCT Number | C127792 | Clinicaltrials.gov NCT Number for the Expanded Access Record | |||
| 55 | 2020-03-27 | TSPARM | Expanded Access Status | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | Status indicating availability of an experimental drug or device outside any clinical trial protocol. (clinicaltrials.gov) | Expanded Access Status | C127793 | Trial Expanded Access Status | |||
| 56 | 2020-03-27 | TSPARM | Exploratory Outcome Measure | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The outcome measure(s) that is part of a pre-specified analysis plan used to evaluate the exploratory endpoint(s) associated with exploratory study objective(s) and/or any other measures, excluding post-hoc measures, that are a focus of the study. (After clinicaltrials.gov) | Exploratory Outcome Measure | C98724 | Exploratory Outcome Measure | |||
| 57 | 2020-03-27 | TSPARM | Extension Trial Indicator | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | An indication as to whether the clinical trial is an extension trial. | Extension Trial Indicator | C139274 | Extension Trial Indicator | |||
| 58 | 2020-03-27 | TSPARM | FDA Technical Specification | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The name and version of the FDA technical specification that is being used in the study submission. | FDA Technical Specification | C156603 | FDA Technical Specification Name and Version | |||
| 59 | 2020-03-27 | TSPARM | FDA-Regulated Device Study Indicator | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | An indication as to whether the study involves an FDA-regulated device. | FDA-Regulated Device Study Indicator | C123629 | FDA-Regulated Device Study Indicator | |||
| 60 | 2020-03-27 | TSPARM | FDA-Regulated Drug Study Indicator | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | An indication as to whether the study involves an FDA-regulated drug. | FDA-Regulated Drug Study Indicator | C123630 | FDA-Regulated Drug Study Indicator | |||
| 61 | 2020-03-27 | TSPARM | Healthy Subject Indicator | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | Indicate if persons who have not had the condition(s) being studied or otherwise related conditions or symptoms, as specified in the eligibility requirements, may participate in the study. | Healthy Subject Indicator | C98737 | Healthy Subject Indicator | |||
| 62 | 2020-03-27 | TSPARM | Intervention Model | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The general design of the strategy for assigning interventions to participants in a clinical study. (clinicaltrials.gov) | Intervention Model | C98746 | Intervention Model | |||
| 63 | 2020-03-27 | TSPARM | Intervention Type | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The kind of product or procedure studied in a trial. | Intervention Type | C98747 | Intervention Type | |||
| 64 | 2020-03-27 | TSPARM | Investigational Therapy or Treatment | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The investigational product under study. | Investigational Therapy or Treatment | C41161 | Protocol Agent | |||
| 65 | 2020-03-27 | TSPARM | Multiple Site EU State Trial Indicator | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | An indication as to whether the clinical study is being conducted at multiple sites within the European Union member state concerned by the application. | Multiple Site EU State Trial Indicator | C127794 | Multiple Site European Union State Trial Indicator | |||
| 66 | 2020-03-27 | TSPARM | Number of Groups/Cohorts | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The number of groups or cohorts that are part of the study. | Number of Groups/Cohorts | C126063 | Number of Groups or Cohorts | |||
| 67 | 2020-03-27 | TSPARM | Number of Trial Sites EU State | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The total number of trial sites within the European Union member state concerned by the application. | Number of Trial Sites EU State | C127795 | Number of Trial Sites within European Union State | |||
| 68 | 2020-03-27 | TSPARM | Obs Study Population Description | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | A description of the population from which the groups or cohorts will be selected within an observational study. | Obs Study Population Description | C126066 | Observational Study Population Description | |||
| 69 | 2020-03-27 | TSPARM | Obs Study Sampling Method Description | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | A textual description of the sampling method used to assign study participants into groups or cohorts within an observational study. | Obs Study Sampling Method Description | C126068 | Observational Study Sampling Method Description | |||
| 70 | 2020-03-27 | TSPARM | Observational Model | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The trial design developed to compare biomedical and/or health outcomes in pre-defined and non-assigned groups of individuals. | Observational Model | C126064 | Observational Model | |||
| 71 | 2020-03-27 | TSPARM | Observational Study Sampling Method | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The sampling method used to assign study participants into groups or cohorts within an observational study. | Observational Study Sampling Method | C126067 | Observational Study Sampling Method | |||
| 72 | 2020-03-27 | TSPARM | Observational Time Perspective | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The temporal relationship between the observation period and time of subject enrollment. (ClinicalTrials.gov) | Observational Time Perspective | C126065 | Observational Time Perspective of Study | |||
| 73 | 2020-03-27 | TSPARM | Pediatric Investigation Plan Indicator | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | An indication as to whether the trial is part of a pediatric investigation plan (PIP). | Pediatric Investigation Plan Indicator | C126069 | Pediatric Investigation Plan Indicator | |||
| 74 | 2020-03-27 | TSPARM | Pediatric Postmarket Study Indicator | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | An indication as to whether the study is a pediatric postmarket study. | Pediatric Postmarket Study Indicator | C123631 | Pediatric Postmarket Study Indicator | |||
| 75 | 2020-03-27 | TSPARM | Pediatric Study Indicator | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | An indication as to whether the study is a pediatric study. | Pediatric Study Indicator | C123632 | Pediatric Study Indicator | |||
| 76 | 2020-03-27 | TSPARM | Pharmacologic Class | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The pharmacological class of the investigational product. | Pharmacologic Class | C98768 | Pharmacological Class of Investigational Therapy | |||
| 77 | 2020-03-27 | TSPARM | Planned Country of Investigational Sites | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The country name of planned study facility which has received IRB approval. | Planned Country of Investigational Sites | C98770 | Planned Country of Investigational Site | |||
| 78 | 2020-03-27 | TSPARM | Planned Maximum Age of Subjects | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The anticipated maximum age of the subjects to be entered in a clinical trial. (NCI) | Planned Maximum Age of Subjects | C49694 | Planned Maximum Age of Subjects | |||
| 79 | 2020-03-27 | TSPARM | Planned Minimum Age of Subjects | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The anticipated minimum age of the subjects to be entered in a clinical trial. (NCI) | Planned Minimum Age of Subjects | C49693 | Planned Minimum Age of Subjects | |||
| 80 | 2020-03-27 | TSPARM | Planned Number of Arms | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The planned number of intervention groups. | Planned Number of Arms | C98771 | Planned Number of Arms | |||
| 81 | 2020-03-27 | TSPARM | Planned Number of Subjects | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The planned number of subjects to be entered in a clinical trial. (NCI) | Anticipated Enrollment; Planned Enrollment; Planned Number of Subjects; Target Enrollment | C49692 | Planned Subject Number | |||
| 82 | 2020-03-27 | TSPARM | Planned Treatment Duration | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The period of time during which the treatment is intended to be given. | Planned Treatment Duration | C139276 | Planned Treatment Duration | |||
| 83 | 2020-03-27 | TSPARM | Planned Trial Duration | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The approximate period of time over which the clinical trial is expected to occur. | Planned Trial Duration | C127796 | Planned Trial Duration | |||
| 84 | 2020-03-27 | TSPARM | Post Authorization Safety Study Ind | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | An indication as to whether the clinical study is a post authorization safety study. | Post Authorization Safety Study Ind | C139275 | Post Authorization Safety Study Indicator | |||
| 85 | 2020-03-27 | TSPARM | Primary Outcome Measure | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The outcome measure(s) of greatest importance specified in the protocol, usually the one(s) used in the power calculation, to evaluate the primary endpoint(s) associated with the primary study objective(s). (After Clinicaltrials.gov) | Primary Outcome Measure | C98772 | Primary Outcome Measure | |||
| 86 | 2020-03-27 | TSPARM | Protocol Keyword | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | A word or small set of words designed to convey the focus of the protocol. | Protocol Keyword | C126062 | Protocol Keyword | |||
| 87 | 2020-03-27 | TSPARM | Protocol Risk Assessment | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The potential future harm that may arise from a protocol-related activity. | Protocol Risk Assessment | C139277 | Protocol Risk Assessment | |||
| 88 | 2020-03-27 | TSPARM | PubMed ID for Citation Used in Study | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | A globally unique identifier for a biomedical article, as assigned by PubMed. | PubMed ID for Citation Used in Study | C127797 | PubMed Identifier for Citation Used in Study | |||
| 89 | 2020-03-27 | TSPARM | Randomization Quotient | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The randomization quotient is the number of planned subjects to be exposed to investigational therapy, independent of dose or other factors, divided by the total number of planned subjects. | Randomization Quotient | C98775 | Randomization Quotient | |||
| 90 | 2020-03-27 | TSPARM | Rare Disease Indicator | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | An indication as to whether the condition under study is considered a rare disease. | Rare Disease Indicator | C126070 | Rare Disease Indicator | |||
| 91 | 2020-03-27 | TSPARM | Registry Identifier | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | Identification numbers assigned to the protocol by clinicaltrials.gov, EudraCT, or other registries. | Registry Identifier | C98714 | Clinical Trial Registry Identifier | |||
| 92 | 2020-03-27 | TSPARM | Relapse Criteria | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | A standard from which a judgment concerning a disease relapse can be established. | Relapse Criteria | C117961 | Relapse Criteria | |||
| 93 | 2020-03-27 | TSPARM | Request for XML Copy of Study Indicator | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | An indication as to whether the registrant would like to receive an XML copy of their study as saved on EudraCT. | Request for XML Copy of Study Indicator | C127798 | Study Saved as XML Indicator | |||
| 94 | 2020-03-27 | TSPARM | Resubmission Letter | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | An alphabetic character that describes the incremental order of trial resubmissions. | Resubmission Letter | C126071 | Resubmission Letter | |||
| 95 | 2020-03-27 | TSPARM | Retained Biospecimen Description | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | A textual description of the specimen types that are retained as reserve samples. | Retained Biospecimen Description | C126072 | Retained Biospecimen Description | |||
| 96 | 2020-03-27 | TSPARM | Route of Administration | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The course by which a substance is administered in order to reach the site of action in the body. | Route of Administration | C38114 | Route of Administration | |||
| 97 | 2020-03-27 | TSPARM | SDTM IG Version | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The version of the CDISC Study Data Tabulation Model implementation guide that is being used in the study submission. | SDTM IG Version; SDTM Implementation Guide Version | C156604 | Study Data Tabulation Model Implementation Guide Version | |||
| 98 | 2020-03-27 | TSPARM | SDTM Version | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The version of the CDISC Study Data Tabulation Model that is being used in the study submission. | SDTM Version | C156605 | Study Data Tabulation Model Version | |||
| 99 | 2020-03-27 | TSPARM | SUSAR Reporting to EVCTM Indicator | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | An indication as to whether suspected unexpected serious adverse reactions (SUSAR) will be reported to a EudraVigiliance clinical trial module (EVCTM). | SUSAR Reporting to EVCTM Indicator | C126073 | SUSAR Reporting to EudraVigiliance Clinical Trial Module Indicator | |||
| 100 | 2020-03-27 | TSPARM | SUSAR Reporting to NCA Indicator | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | An indication as to whether suspected unexpected serious adverse reactions (SUSAR) will be reported to national competent authorities (NCA). | SUSAR Reporting to NCA Indicator | C126074 | SUSAR Reporting to National Competent Authority Indicator | |||
| 101 | 2020-03-27 | TSPARM | Secondary Outcome Measure | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The outcome measure(s) that is part of a pre-specified analysis plan used to evaluate the secondary endpoint(s) associated with secondary study objective(s) and/or used to evaluate any measure(s) ancillary to the primary or secondary endpoint(s). (After Clinicaltrials.gov). | Secondary Outcome Measure | C98781 | Secondary Outcome Measure | |||
| 102 | 2020-03-27 | TSPARM | Secure Delivery XML Required Indicator | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | An indication as to whether the XML copy of the EudraCT application requires secure E-mail delivery. | Secure Delivery XML Required Indicator | C127799 | Requires Secure Email Delivery of XML Indicator | |||
| 103 | 2020-03-27 | TSPARM | Severity Criteria | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | A standard from which a judgment concerning the severity of an event, disease or condition can be established. | Severity Criteria | C117962 | Severity Criteria | |||
| 104 | 2020-03-27 | TSPARM | Sex of Participants | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The specific sex, either male, female, or mixed of the subject group being studied. (NCI) | Sex of Participants | C49696 | Sex of Study Group | |||
| 105 | 2020-03-27 | TSPARM | Single Site EU State Trial Indicator | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | An indication as to whether the clinical study is being conducted at only one site within the European Union member state concerned by the application. | Single Site EU State Trial Indicator | C127800 | Single Site European Union State Trial Indicator | |||
| 106 | 2020-03-27 | TSPARM | Stable Disease Minimum Duration | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The protocol specified minimum amount of time needed to meet the definition of stable disease. | Stable Disease Minimum Duration | C98783 | Stable Disease Minimum Duration | |||
| 107 | 2020-03-27 | TSPARM | Stratification Factor | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | Selected factors that are used during randomization to ensure there is balance of these factors across all subjects within each arm of a study. The subject level values of these factors may be used as fixed effects in statistical models and for sensitivity analyses. | Stratification Factor | C16153 | Stratification Factors | |||
| 108 | 2020-03-27 | TSPARM | Study End Date | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The date on which the final data item for a clinical study was collected from the last study participant (that is, last subject, last visit, or as otherwise defined in the study protocol). (CDISC Glossary) | Study End Date | C90462 | Clinical Study End Date | |||
| 109 | 2020-03-27 | TSPARM | Study Start Date | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The earliest date of informed consent among any subject (Date/Time of Informed Consent, RFICDTC) that enrolled in the study. For studies conducted without informed consent (ie. emergency use) use the date of treatment. Dates for subjects who were screen failures are not included. | Study Start Date | C69208 | Study Start Date | |||
| 110 | 2020-03-27 | TSPARM | Study Stop Rules | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The rule, regulation and/or condition that determines the point in time when a clinical trial will be terminated. (NCI) | Study Stop Rules | C49698 | Study Stop Rule | |||
| 111 | 2020-03-27 | TSPARM | Study Type | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | Describes the role the study plays in determining the interventions a subject receives. | Study Type | C142175 | Study Type | |||
| 112 | 2020-03-27 | TSPARM | Substudy Details | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | A textual description of the substudy. | Substudy Details | C126075 | Substudy Details | |||
| 113 | 2020-03-27 | TSPARM | Substudy Planned Indicator | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | An indication as to whether a study performed on a subgroup of subjects included in the original trial (substudy) is planned for the current study. | Substudy Planned Indicator | C126076 | Substudy Planned Indicator | |||
| 114 | 2020-03-27 | TSPARM | Target Follow-Up Duration | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The anticipated time period over which each study participant is to be followed. (ClinicalTrials.gov) | Target Follow-Up Duration | C126077 | Planned Follow-Up Duration | |||
| 115 | 2020-03-27 | TSPARM | Therapeutic Area | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | A knowledge field that focuses on research and development of specific treatments for diseases and pathologic findings, as well as prevention of conditions that negatively impact the health of an individual. (NCI) | Therapeutic Area | C101302 | Therapeutic Area | |||
| 116 | 2020-03-27 | TSPARM | Trial Blinding Schema | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The type of experimental design used to describe the level of awareness of the clinical trial subjects and/or investigators of the intervention(s) that they are receiving and/or administering. | Trial Blinding Schema | C49658 | Trial Blinding Schema | |||
| 117 | 2020-03-27 | TSPARM | Trial Disease/Condition Indication | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The condition, disease or disorder that the clinical trial is intended to investigate or address. | Trial Disease/Condition Indication | C112038 | Trial Indication | |||
| 118 | 2020-03-27 | TSPARM | Trial Exploratory Objective | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The exploratory purpose of the trial. | Trial Exploratory Objective | C163559 | Trial Exploratory Objective | |||
| 119 | 2020-03-27 | TSPARM | Trial Intent Type | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The planned purpose of the therapy, device, or agent under study in the clinical trial. | Trial Intent Type | C49652 | Clinical Study by Intent | |||
| 120 | 2020-03-27 | TSPARM | Trial Length | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | Planned length of observation for a single subject. | Trial Length | C49697 | Trial Length | |||
| 121 | 2020-03-27 | TSPARM | Trial Phase Classification | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | Any defined stage in the lifecycle of a clinical trial. | Trial Phase Classification | C48281 | Trial Phase | |||
| 122 | 2020-03-27 | TSPARM | Trial Primary Objective | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The principal purpose of the trial. | Trial Primary Objective | C85826 | Trial Primary Objective | |||
| 123 | 2020-03-27 | TSPARM | Trial Secondary Objective | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The auxiliary purpose of the trial. | Trial Secondary Objective | C85827 | Trial Secondary Objective | |||
| 124 | 2020-03-27 | TSPARM | Trial Title | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The name of a clinical trial. (NCI) | Trial Title | C49802 | Trial Title | |||
| 125 | 2020-03-27 | TSPARM | Trial Type | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The type of primary outcome or endpoint that the protocol is designed to evaluate. (clinicaltrials.gov) | Trial Scope; Trial Type | C49660 | Trial Type | |||
| 126 | 2020-03-27 | TSPARM | Trial is Randomized | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The process of assigning trial subjects to treatment or control groups using an element of chance to determine the assignments in order to reduce bias. NOTE: Unequal randomization is used to allocate subjects into groups at a differential rate; for example, three subjects may be assigned to a treatment group for every one assigned to the control group. [ICH E6 1.48] See also balanced study. (CDISC glossary) | Trial is Randomized | C25196 | Randomization | |||
| 127 | 2020-03-27 | TSPARM | URL Related to Study | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | The uniform resource locator (URL) related to a particular study. | URL Related to Study | C127801 | Study Protocol Uniform Resource Locator | |||
| 128 | 2020-03-27 | TSPARM | URL Related to Study Description | . | C67152 | Trial Summary Parameter Test Name | Yes | CDISC SDTM Trial Summary Parameter Long Name Terminology | A textual description of the uniform resource locator (URL) related to a particular study. | URL Related to Study Description | C127802 | Study Protocol Uniform Resource Locator Description | |||
| 129 | 2020-03-27 | TSPARMCD | ACTSUB | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | Actual number of subjects enrolled; may include subjects who were not randomized. | Actual Number of Subjects | C98703 | Actual Subject Number | |||
| 130 | 2020-03-27 | TSPARMCD | ADAPT | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | Indicate if the study includes a prospectively planned opportunity for modification of one or more specified aspects of the study design and hypotheses based on analysis of data (usually interim data) from subjects in the study. | Adaptive Design | C146995 | Adaptive Study Design Indicator | |||
| 131 | 2020-03-27 | TSPARMCD | ADDON | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The addition of a therapeutic product to the existing regimen in a clinical trial, where both entities remain as discrete products. | Added on to Existing Treatments | C49703 | Test Product Added to Existing Treatment | |||
| 132 | 2020-03-27 | TSPARMCD | AGEMAX | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The anticipated maximum age of the subjects to be entered in a clinical trial. (NCI) | Planned Maximum Age of Subjects | C49694 | Planned Maximum Age of Subjects | |||
| 133 | 2020-03-27 | TSPARMCD | AGEMIN | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The anticipated minimum age of the subjects to be entered in a clinical trial. (NCI) | Planned Minimum Age of Subjects | C49693 | Planned Minimum Age of Subjects | |||
| 134 | 2020-03-27 | TSPARMCD | BIOSPRET | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | A textual description as to whether a biospecimen is retained and/or contains DNA. | Biospecimen Retention Contains DNA | C126058 | Biospecimen Retained and/or Contains DNA Indicator | |||
| 135 | 2020-03-27 | TSPARMCD | CITNSTDY | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | A bibliographical reference related to a particular study. | Citation Used in Study | C127788 | Clinical Study Citation | |||
| 136 | 2020-03-27 | TSPARMCD | CMSPSTAT | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The state or condition of the sponsor as pertains to whether the sponsor is considered a commercial entity. | Commercial Sponsor Status | C127789 | Sponsor Commercial Status | |||
| 137 | 2020-03-27 | TSPARMCD | COMPTRT | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | A therapeutically active agent that is intended to provide reference measurements for the experimental protocol of a clinical trial. | Comparative Treatment Name | C68612 | Active Comparator Drug | |||
| 138 | 2020-03-27 | TSPARMCD | CRMDUR | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The protocol specified minimum amount of time needed to meet the definition of a confirmed response to treatment. | Confirmed Response Minimum Duration | C98715 | Confirmed Response Minimum Duration | |||
| 139 | 2020-03-27 | TSPARMCD | CSRARDTC | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The date when the clinical study report was archived. | Clinical Study Report Archive Date | C139273 | Clinical Study Report Archive Date | |||
| 140 | 2020-03-27 | TSPARMCD | CTAUG | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The name and version of the CDISC therapeutic area user guide that is being used in the study submission. | CDISC Therapeutic Area User Guide | C156602 | CDISC Therapeutic Area User Guide Name and Version | |||
| 141 | 2020-03-27 | TSPARMCD | CURTRT | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The literal identifier of the therapy or medication that is currently being given per protocol. | Current Therapy or Treatment | C85582 | Current Therapy | |||
| 142 | 2020-03-27 | TSPARMCD | DCUTDESC | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | Text that describes the cutoff date. | Data Cutoff Description | C98718 | Data Cutoff Date Description | |||
| 143 | 2020-03-27 | TSPARMCD | DCUTDTC | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | A date which indicates any data collected by this date will be used for analysis. | Data Cutoff Date | C98717 | Data Cutoff Date | |||
| 144 | 2020-03-27 | TSPARMCD | DGFCRIT | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | A standard by which the determination of delayed graft function (DGF) is established. | Delayed Graft Function Diagnostic Criteria; Delayed Graft Function Dx Criteria | C135514 | Delayed Graft Function Diagnostic Criteria Name | |||
| 145 | 2020-03-27 | TSPARMCD | DMCIND | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | An indication as to whether the clinical trial has an appointed data monitoring committee. | Data Monitoring Committee Indicator | C127790 | Data Monitoring Committee Indicator | |||
| 146 | 2020-03-27 | TSPARMCD | DOSE | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The amount of drug administered to a patient or test subject at one time or the total quantity administered. [AMA Manual of Style] (CDISC Glossary) | Dose Level; Dose per Administration | C25488 | Dose | |||
| 147 | 2020-03-27 | TSPARMCD | DOSFRM | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The pharmaceutical dosage form of the drug administered. | Dose Form | C42636 | Pharmaceutical Dosage Form | |||
| 148 | 2020-03-27 | TSPARMCD | DOSFRQ | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The number of doses administered per a specific interval. | Dosing Frequency | C89081 | Dose Frequency | |||
| 149 | 2020-03-27 | TSPARMCD | DOSRGM | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The planned schedule for the administration of an agent (such as a drug, substance or radiation). | Dose Regimen | C71137 | Dose Regimen | |||
| 150 | 2020-03-27 | TSPARMCD | DOSU | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The unit of measure for the dosage form. | Dose Units | C73558 | Dosage Form Unit | |||
| 151 | 2020-03-27 | TSPARMCD | DXCRIT | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | A standard from which a judgment concerning a medical diagnosis can be established. | Diagnostic Criteria | C117960 | Diagnostic Criteria | |||
| 152 | 2020-03-27 | TSPARMCD | EGBLIND | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | Indicates whether assessors of ECGs for this study were blinded to subject identity, timing and treatment. | ECG Reading Blinded | C119560 | ECG Evaluator Blinding Parameters | |||
| 153 | 2020-03-27 | TSPARMCD | EGCTMON | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | Indicates whether the 10-second ECGs for this study were extracted from a continuous recording. | ECG Continuous Monitoring | C119561 | ECG Continuous Monitoring Indicator | |||
| 154 | 2020-03-27 | TSPARMCD | EGLEADPR | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The ECG lead which was planned to be used for ECG interval measurements for this study. | ECG Planned Primary Lead | C119562 | ECG Planned Primary Lead for Study | |||
| 155 | 2020-03-27 | TSPARMCD | EGLEADSM | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | Indicates whether all ECG interval measurements for the study were based on the same lead. | ECG Used Same Lead | C119563 | ECG Used Same Lead Indicator | |||
| 156 | 2020-03-27 | TSPARMCD | EGRDMETH | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The degree of automation involved in assessing the ECGs for this study. | ECG Read Method | C119564 | ECG Read Method Degree of Automation | |||
| 157 | 2020-03-27 | TSPARMCD | EGREPLBL | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | Indicates whether this study includes replicate ECGs for time points during the baseline portion of the study. | ECG Replicates at Baseline | C119565 | ECG Replicates at Baseline Indicator | |||
| 158 | 2020-03-27 | TSPARMCD | EGREPLTR | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | Indicates whether this study includes replicate ECGs for time points during the on-treatment portion of the study. | ECG Replicates On-Treatment | C119566 | ECG Replicates On-Treatment Indicator | |||
| 159 | 2020-03-27 | TSPARMCD | EGTWVALG | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The algorithm used to identify the end of the T wave for ECGs for this study. | ECG Twave Algorithm | C119582 | ECG T Wave Algorithm | |||
| 160 | 2020-03-27 | TSPARMCD | EMAILXML | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The Email address to which copies of the XML format of the EudraCT application should be sent. | Email Address for XML File | C127791 | E-mail Address for XML File Feedback | |||
| 161 | 2020-03-27 | TSPARMCD | EMPIPDCN | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | An alphanumeric code assigned by the European Medicines Agency (EMA) to an EMA regulatory decision for a pediatric investigation plan (PIP). | EMA Decision Number for PIP | C126059 | EMA Decision Number for Pediatric Investigation Plan | |||
| 162 | 2020-03-27 | TSPARMCD | EURSBIND | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | An indication as to whether the trial being submitted to the EudraCT is a trial that has been previously submitted to the EudraCT system. | EudraCT Resubmission Indicator | C126060 | EudraCT Resubmission Indicator | |||
| 163 | 2020-03-27 | TSPARMCD | EVSNDID | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | A unique identifier assigned to the organization that is transmitting an adverse drug reaction report to the EudraVigilance system. | EudraVigilance Sender ID | C126061 | EudraVigilance Sender Identifier | |||
| 164 | 2020-03-27 | TSPARMCD | EVSNDORG | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The name of the group or institution that is transmitting an adverse drug reaction report to the EudraVigilance system. | EudraVigilance Sender Organization | C126090 | EudraVigilance Sender Organization | |||
| 165 | 2020-03-27 | TSPARMCD | EXPARECN | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The unique alphanumeric identifier for the study with associated expanded access record, as assigned by the clinicaltrials.gov protocol registration and results system (PRS). | Expanded Access Record NCT Number | C127792 | Clinicaltrials.gov NCT Number for the Expanded Access Record | |||
| 166 | 2020-03-27 | TSPARMCD | EXPASTAT | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | Status indicating availability of an experimental drug or device outside any clinical trial protocol. (clinicaltrials.gov) | Expanded Access Status | C127793 | Trial Expanded Access Status | |||
| 167 | 2020-03-27 | TSPARMCD | EXTTIND | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | An indication as to whether the clinical trial is an extension trial. | Extension Trial Indicator | C139274 | Extension Trial Indicator | |||
| 168 | 2020-03-27 | TSPARMCD | FCNTRY | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The country name of planned study facility which has received IRB approval. | Planned Country of Investigational Sites | C98770 | Planned Country of Investigational Site | |||
| 169 | 2020-03-27 | TSPARMCD | FDADEIND | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | An indication as to whether the study involves an FDA-regulated device. | FDA-Regulated Device Study Indicator | C123629 | FDA-Regulated Device Study Indicator | |||
| 170 | 2020-03-27 | TSPARMCD | FDADRIND | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | An indication as to whether the study involves an FDA-regulated drug. | FDA-Regulated Drug Study Indicator | C123630 | FDA-Regulated Drug Study Indicator | |||
| 171 | 2020-03-27 | TSPARMCD | FDATCHSP | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The name and version of the FDA technical specification that is being used in the study submission. | FDA Technical Specification | C156603 | FDA Technical Specification Name and Version | |||
| 172 | 2020-03-27 | TSPARMCD | HLTSUBJI | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | Indicate if persons who have not had the condition(s) being studied or otherwise related conditions or symptoms, as specified in the eligibility requirements, may participate in the study. | Healthy Subject Indicator | C98737 | Healthy Subject Indicator | |||
| 173 | 2020-03-27 | TSPARMCD | INDIC | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The condition, disease or disorder that the clinical trial is intended to investigate or address. | Trial Disease/Condition Indication | C112038 | Trial Indication | |||
| 174 | 2020-03-27 | TSPARMCD | INTMODEL | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The general design of the strategy for assigning interventions to participants in a clinical study. (clinicaltrials.gov) | Intervention Model | C98746 | Intervention Model | |||
| 175 | 2020-03-27 | TSPARMCD | INTTYPE | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The kind of product or procedure studied in a trial. | Intervention Type | C98747 | Intervention Type | |||
| 176 | 2020-03-27 | TSPARMCD | KEYWORD | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | A word or small set of words designed to convey the focus of the protocol. | Protocol Keyword | C126062 | Protocol Keyword | |||
| 177 | 2020-03-27 | TSPARMCD | LENGTH | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | Planned length of observation for a single subject. | Trial Length | C49697 | Trial Length | |||
| 178 | 2020-03-27 | TSPARMCD | MNFCNTRY | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The name of the country within which the final product under study is produced. | Country of Manufacture | C124455 | Country of Manufacture | |||
| 179 | 2020-03-27 | TSPARMCD | MSEUTIND | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | An indication as to whether the clinical study is being conducted at multiple sites within the European Union member state concerned by the application. | Multiple Site EU State Trial Indicator | C127794 | Multiple Site European Union State Trial Indicator | |||
| 180 | 2020-03-27 | TSPARMCD | NARMS | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The planned number of intervention groups. | Planned Number of Arms | C98771 | Planned Number of Arms | |||
| 181 | 2020-03-27 | TSPARMCD | NCOHORT | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The number of groups or cohorts that are part of the study. | Number of Groups/Cohorts | C126063 | Number of Groups or Cohorts | |||
| 182 | 2020-03-27 | TSPARMCD | NUMSEUST | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The total number of trial sites within the European Union member state concerned by the application. | Number of Trial Sites EU State | C127795 | Number of Trial Sites within European Union State | |||
| 183 | 2020-03-27 | TSPARMCD | OBJEXP | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The exploratory purpose of the trial. | Trial Exploratory Objective | C163559 | Trial Exploratory Objective | |||
| 184 | 2020-03-27 | TSPARMCD | OBJPRIM | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The principal purpose of the trial. | Trial Primary Objective | C85826 | Trial Primary Objective | |||
| 185 | 2020-03-27 | TSPARMCD | OBJSEC | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The auxiliary purpose of the trial. | Trial Secondary Objective | C85827 | Trial Secondary Objective | |||
| 186 | 2020-03-27 | TSPARMCD | OBSMODEL | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The trial design developed to compare biomedical and/or health outcomes in pre-defined and non-assigned groups of individuals. | Observational Model | C126064 | Observational Model | |||
| 187 | 2020-03-27 | TSPARMCD | OBSTIMP | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The temporal relationship between the observation period and time of subject enrollment. (ClinicalTrials.gov) | Observational Time Perspective | C126065 | Observational Time Perspective of Study | |||
| 188 | 2020-03-27 | TSPARMCD | OBSTPOPD | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | A description of the population from which the groups or cohorts will be selected within an observational study. | Obs Study Population Description | C126066 | Observational Study Population Description | |||
| 189 | 2020-03-27 | TSPARMCD | OBSTSMM | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The sampling method used to assign study participants into groups or cohorts within an observational study. | Observational Study Sampling Method | C126067 | Observational Study Sampling Method | |||
| 190 | 2020-03-27 | TSPARMCD | OBSTSMMD | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | A textual description of the sampling method used to assign study participants into groups or cohorts within an observational study. | Obs Study Sampling Method Description | C126068 | Observational Study Sampling Method Description | |||
| 191 | 2020-03-27 | TSPARMCD | OUTMSADD | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | Additional key measures that will be used to evaluate the intervention(s) or, for observational studies, that are a focus of the study. These are the outcome measures not used to assess primary or secondary objectives. | Additional Outcome Measure | C156601 | Additional Outcome Measure | |||
| 192 | 2020-03-27 | TSPARMCD | OUTMSEXP | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The outcome measure(s) that is part of a pre-specified analysis plan used to evaluate the exploratory endpoint(s) associated with exploratory study objective(s) and/or any other measures, excluding post-hoc measures, that are a focus of the study. (After clinicaltrials.gov) | Exploratory Outcome Measure | C98724 | Exploratory Outcome Measure | |||
| 193 | 2020-03-27 | TSPARMCD | OUTMSPRI | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The outcome measure(s) of greatest importance specified in the protocol, usually the one(s) used in the power calculation, to evaluate the primary endpoint(s) associated with the primary study objective(s). (After Clinicaltrials.gov) | Primary Outcome Measure | C98772 | Primary Outcome Measure | |||
| 194 | 2020-03-27 | TSPARMCD | OUTMSSEC | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The outcome measure(s) that is part of a pre-specified analysis plan used to evaluate the secondary endpoint(s) associated with secondary study objective(s) and/or used to evaluate any measure(s) ancillary to the primary or secondary endpoint(s). (After Clinicaltrials.gov). | Secondary Outcome Measure | C98781 | Secondary Outcome Measure | |||
| 195 | 2020-03-27 | TSPARMCD | PASSIND | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | An indication as to whether the clinical study is a post authorization safety study. | Post Authorization Safety Study Ind | C139275 | Post Authorization Safety Study Indicator | |||
| 196 | 2020-03-27 | TSPARMCD | PCLAS | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The pharmacological class of the investigational product. | Pharmacologic Class | C98768 | Pharmacological Class of Investigational Therapy | |||
| 197 | 2020-03-27 | TSPARMCD | PDPSTIND | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | An indication as to whether the study is a pediatric postmarket study. | Pediatric Postmarket Study Indicator | C123631 | Pediatric Postmarket Study Indicator | |||
| 198 | 2020-03-27 | TSPARMCD | PDSTIND | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | An indication as to whether the study is a pediatric study. | Pediatric Study Indicator | C123632 | Pediatric Study Indicator | |||
| 199 | 2020-03-27 | TSPARMCD | PIPIND | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | An indication as to whether the trial is part of a pediatric investigation plan (PIP). | Pediatric Investigation Plan Indicator | C126069 | Pediatric Investigation Plan Indicator | |||
| 200 | 2020-03-27 | TSPARMCD | PLANSUB | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The planned number of subjects to be entered in a clinical trial. (NCI) | Anticipated Enrollment; Planned Enrollment; Planned Number of Subjects; Target Enrollment | C49692 | Planned Subject Number | |||
| 201 | 2020-03-27 | TSPARMCD | PLNTRDUR | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The approximate period of time over which the clinical trial is expected to occur. | Planned Trial Duration | C127796 | Planned Trial Duration | |||
| 202 | 2020-03-27 | TSPARMCD | PROTRSK | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The potential future harm that may arise from a protocol-related activity. | Protocol Risk Assessment | C139277 | Protocol Risk Assessment | |||
| 203 | 2020-03-27 | TSPARMCD | PTRTDUR | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The period of time during which the treatment is intended to be given. | Planned Treatment Duration | C139276 | Planned Treatment Duration | |||
| 204 | 2020-03-27 | TSPARMCD | PUBMEDID | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | A globally unique identifier for a biomedical article, as assigned by PubMed. | PubMed ID for Citation Used in Study | C127797 | PubMed Identifier for Citation Used in Study | |||
| 205 | 2020-03-27 | TSPARMCD | RANDOM | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The process of assigning trial subjects to treatment or control groups using an element of chance to determine the assignments in order to reduce bias. NOTE: Unequal randomization is used to allocate subjects into groups at a differential rate; for example, three subjects may be assigned to a treatment group for every one assigned to the control group. [ICH E6 1.48] See also balanced study. (CDISC glossary) | Trial is Randomized | C25196 | Randomization | |||
| 206 | 2020-03-27 | TSPARMCD | RANDQT | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The randomization quotient is the number of planned subjects to be exposed to investigational therapy, independent of dose or other factors, divided by the total number of planned subjects. | Randomization Quotient | C98775 | Randomization Quotient | |||
| 207 | 2020-03-27 | TSPARMCD | RDIND | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | An indication as to whether the condition under study is considered a rare disease. | Rare Disease Indicator | C126070 | Rare Disease Indicator | |||
| 208 | 2020-03-27 | TSPARMCD | REGID | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | Identification numbers assigned to the protocol by clinicaltrials.gov, EudraCT, or other registries. | Registry Identifier | C98714 | Clinical Trial Registry Identifier | |||
| 209 | 2020-03-27 | TSPARMCD | RESUBLTR | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | An alphabetic character that describes the incremental order of trial resubmissions. | Resubmission Letter | C126071 | Resubmission Letter | |||
| 210 | 2020-03-27 | TSPARMCD | RLPSCRIT | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | A standard from which a judgment concerning a disease relapse can be established. | Relapse Criteria | C117961 | Relapse Criteria | |||
| 211 | 2020-03-27 | TSPARMCD | ROUTE | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The course by which a substance is administered in order to reach the site of action in the body. | Route of Administration | C38114 | Route of Administration | |||
| 212 | 2020-03-27 | TSPARMCD | RTSPCDES | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | A textual description of the specimen types that are retained as reserve samples. | Retained Biospecimen Description | C126072 | Retained Biospecimen Description | |||
| 213 | 2020-03-27 | TSPARMCD | RXMLCIND | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | An indication as to whether the registrant would like to receive an XML copy of their study as saved on EudraCT. | Request for XML Copy of Study Indicator | C127798 | Study Saved as XML Indicator | |||
| 214 | 2020-03-27 | TSPARMCD | SDMDUR | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The protocol specified minimum amount of time needed to meet the definition of stable disease. | Stable Disease Minimum Duration | C98783 | Stable Disease Minimum Duration | |||
| 215 | 2020-03-27 | TSPARMCD | SDTIGVER | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The version of the CDISC Study Data Tabulation Model implementation guide that is being used in the study submission. | SDTM IG Version; SDTM Implementation Guide Version | C156604 | Study Data Tabulation Model Implementation Guide Version | |||
| 216 | 2020-03-27 | TSPARMCD | SDTMVER | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The version of the CDISC Study Data Tabulation Model that is being used in the study submission. | SDTM Version | C156605 | Study Data Tabulation Model Version | |||
| 217 | 2020-03-27 | TSPARMCD | SDXMLIND | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | An indication as to whether the XML copy of the EudraCT application requires secure E-mail delivery. | Secure Delivery XML Required Indicator | C127799 | Requires Secure Email Delivery of XML Indicator | |||
| 218 | 2020-03-27 | TSPARMCD | SENDTC | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The date on which the final data item for a clinical study was collected from the last study participant (that is, last subject, last visit, or as otherwise defined in the study protocol). (CDISC Glossary) | Study End Date | C90462 | Clinical Study End Date | |||
| 219 | 2020-03-27 | TSPARMCD | SEVCRIT | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | A standard from which a judgment concerning the severity of an event, disease or condition can be established. | Severity Criteria | C117962 | Severity Criteria | |||
| 220 | 2020-03-27 | TSPARMCD | SEXPOP | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The specific sex, either male, female, or mixed of the subject group being studied. (NCI) | Sex of Participants | C49696 | Sex of Study Group | |||
| 221 | 2020-03-27 | TSPARMCD | SPONSOR | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | An entity that is responsible for the initiation, management, and/or financing of a clinical study. | Clinical Study Sponsor; Sponsor; Study Sponsor | C70793 | Clinical Study Sponsor | |||
| 222 | 2020-03-27 | TSPARMCD | SREVIND | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | An indication as to whether suspected unexpected serious adverse reactions (SUSAR) will be reported to a EudraVigiliance clinical trial module (EVCTM). | SUSAR Reporting to EVCTM Indicator | C126073 | SUSAR Reporting to EudraVigiliance Clinical Trial Module Indicator | |||
| 223 | 2020-03-27 | TSPARMCD | SRNCAIND | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | An indication as to whether suspected unexpected serious adverse reactions (SUSAR) will be reported to national competent authorities (NCA). | SUSAR Reporting to NCA Indicator | C126074 | SUSAR Reporting to National Competent Authority Indicator | |||
| 224 | 2020-03-27 | TSPARMCD | SSEUTIND | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | An indication as to whether the clinical study is being conducted at only one site within the European Union member state concerned by the application. | Single Site EU State Trial Indicator | C127800 | Single Site European Union State Trial Indicator | |||
| 225 | 2020-03-27 | TSPARMCD | SSTDTC | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The earliest date of informed consent among any subject (Date/Time of Informed Consent, RFICDTC) that enrolled in the study. For studies conducted without informed consent (ie. emergency use) use the date of treatment. Dates for subjects who were screen failures are not included. | Study Start Date | C69208 | Study Start Date | |||
| 226 | 2020-03-27 | TSPARMCD | SSTDYDTL | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | A textual description of the substudy. | Substudy Details | C126075 | Substudy Details | |||
| 227 | 2020-03-27 | TSPARMCD | SSTDYIND | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | An indication as to whether a study performed on a subgroup of subjects included in the original trial (substudy) is planned for the current study. | Substudy Planned Indicator | C126076 | Substudy Planned Indicator | |||
| 228 | 2020-03-27 | TSPARMCD | STOPRULE | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The rule, regulation and/or condition that determines the point in time when a clinical trial will be terminated. (NCI) | Study Stop Rules | C49698 | Study Stop Rule | |||
| 229 | 2020-03-27 | TSPARMCD | STRATFCT | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | Selected factors that are used during randomization to ensure there is balance of these factors across all subjects within each arm of a study. The subject level values of these factors may be used as fixed effects in statistical models and for sensitivity analyses. | Stratification Factor | C16153 | Stratification Factors | |||
| 230 | 2020-03-27 | TSPARMCD | STYPE | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | Describes the role the study plays in determining the interventions a subject receives. | Study Type | C142175 | Study Type | |||
| 231 | 2020-03-27 | TSPARMCD | TBLIND | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The type of experimental design used to describe the level of awareness of the clinical trial subjects and/or investigators of the intervention(s) that they are receiving and/or administering. | Trial Blinding Schema | C49658 | Trial Blinding Schema | |||
| 232 | 2020-03-27 | TSPARMCD | TCNTRL | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | Comparator against which the study treatment is evaluated. | Control Type | C49647 | Control Type | |||
| 233 | 2020-03-27 | TSPARMCD | TDIGRP | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | A grouping of individuals on the basis of a shared procedure or disease, or lack thereof. | Diagnosis Group | C49650 | Diagnosis Group | |||
| 234 | 2020-03-27 | TSPARMCD | THERAREA | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | A knowledge field that focuses on research and development of specific treatments for diseases and pathologic findings, as well as prevention of conditions that negatively impact the health of an individual. (NCI) | Therapeutic Area | C101302 | Therapeutic Area | |||
| 235 | 2020-03-27 | TSPARMCD | TINDTP | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The planned purpose of the therapy, device, or agent under study in the clinical trial. | Trial Intent Type | C49652 | Clinical Study by Intent | |||
| 236 | 2020-03-27 | TSPARMCD | TITLE | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The name of a clinical trial. (NCI) | Trial Title | C49802 | Trial Title | |||
| 237 | 2020-03-27 | TSPARMCD | TPHASE | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | Any defined stage in the lifecycle of a clinical trial. | Trial Phase Classification | C48281 | Trial Phase | |||
| 238 | 2020-03-27 | TSPARMCD | TRGFUDUR | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The anticipated time period over which each study participant is to be followed. (ClinicalTrials.gov) | Target Follow-Up Duration | C126077 | Planned Follow-Up Duration | |||
| 239 | 2020-03-27 | TSPARMCD | TRT | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The investigational product under study. | Investigational Therapy or Treatment | C41161 | Protocol Agent | |||
| 240 | 2020-03-27 | TSPARMCD | TTYPE | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The type of primary outcome or endpoint that the protocol is designed to evaluate. (clinicaltrials.gov) | Trial Scope; Trial Type | C49660 | Trial Type | |||
| 241 | 2020-03-27 | TSPARMCD | URLSTDY | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | The uniform resource locator (URL) related to a particular study. | URL Related to Study | C127801 | Study Protocol Uniform Resource Locator | |||
| 242 | 2020-03-27 | TSPARMCD | URLSTDYD | . | C66738 | Trial Summary Parameter Test Code | Yes | CDISC SDTM Trial Summary Parameter Short Name Terminology | A textual description of the uniform resource locator (URL) related to a particular study. | URL Related to Study Description | C127802 | Study Protocol Uniform Resource Locator Description |
| Copyright @ www.mycsg.in |
¨ Obs |
· CODELIST_VERSION |
· SCODELIST_ABBREVIATION |
· CODELIST_TYPE |
· CODE |
· DECOD |
· APPLICABLE |
· CRF_VALUE |
¨ NUMERIC_VALUE |
· TFL_VALUE |
· VALUE_CODE |
· SCODELIST_CODE |
· LCODELIST_CODE |
· SCODELIST_EXTENSIBLE |
· LCODELIST_EXTENSIBLE |
· SCODELIST_NAME |
· LCODELIST_ABBREVIATION |
· LCODELIST_NAME |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2020-03-27 | DICTNAM | Single | CDISC CT | . | C163415 | C66788 | Yes | Dictionary Name | ||||||||
| 2 | 2020-03-27 | DICTNAM | Single | COSTART | . | C49471 | C66788 | Yes | Dictionary Name | ||||||||
| 3 | 2020-03-27 | DICTNAM | Single | CTCAE | . | C49704 | C66788 | Yes | Dictionary Name | ||||||||
| 4 | 2020-03-27 | DICTNAM | Single | D-U-N-S NUMBER | . | C134003 | C66788 | Yes | Dictionary Name | ||||||||
| 5 | 2020-03-27 | DICTNAM | Single | ICD | . | C49474 | C66788 | Yes | Dictionary Name | ||||||||
| 6 | 2020-03-27 | DICTNAM | Single | LOINC | . | C49476 | C66788 | Yes | Dictionary Name | ||||||||
| 7 | 2020-03-27 | DICTNAM | Single | MED-RT | . | C163416 | C66788 | Yes | Dictionary Name | ||||||||
| 8 | 2020-03-27 | DICTNAM | Single | MedDRA | . | C43820 | C66788 | Yes | Dictionary Name | ||||||||
| 9 | 2020-03-27 | DICTNAM | Single | SNOMED | . | C53489 | C66788 | Yes | Dictionary Name | ||||||||
| 10 | 2020-03-27 | DICTNAM | Single | UNII | . | C163417 | C66788 | Yes | Dictionary Name | ||||||||
| 11 | 2020-03-27 | DICTNAM | Single | WHO ATC CLASSIFICATION SYSTEM | . | C154331 | C66788 | Yes | Dictionary Name | ||||||||
| 12 | 2020-03-27 | DICTNAM | Single | WHOART | . | C49468 | C66788 | Yes | Dictionary Name | ||||||||
| 13 | 2020-03-27 | DICTNAM | Single | WHODD | . | C49475 | C66788 | Yes | Dictionary Name | ||||||||
| 14 | 2020-03-27 | TSPARMCD | Paired | ACTSUB | Actual Number of Subjects | . | C98703 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 15 | 2020-03-27 | TSPARMCD | Paired | ADAPT | Adaptive Design | . | C146995 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 16 | 2020-03-27 | TSPARMCD | Paired | ADDON | Added on to Existing Treatments | . | C49703 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 17 | 2020-03-27 | TSPARMCD | Paired | AGEMAX | Planned Maximum Age of Subjects | . | C49694 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 18 | 2020-03-27 | TSPARMCD | Paired | AGEMIN | Planned Minimum Age of Subjects | . | C49693 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 19 | 2020-03-27 | TSPARMCD | Paired | BIOSPRET | Biospecimen Retention Contains DNA | . | C126058 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 20 | 2020-03-27 | TSPARMCD | Paired | CITNSTDY | Citation Used in Study | . | C127788 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 21 | 2020-03-27 | TSPARMCD | Paired | CMSPSTAT | Commercial Sponsor Status | . | C127789 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 22 | 2020-03-27 | TSPARMCD | Paired | COMPTRT | Comparative Treatment Name | . | C68612 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 23 | 2020-03-27 | TSPARMCD | Paired | CRMDUR | Confirmed Response Minimum Duration | . | C98715 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 24 | 2020-03-27 | TSPARMCD | Paired | CSRARDTC | Clinical Study Report Archive Date | . | C139273 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 25 | 2020-03-27 | TSPARMCD | Paired | CTAUG | CDISC Therapeutic Area User Guide | . | C156602 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 26 | 2020-03-27 | TSPARMCD | Paired | CURTRT | Current Therapy or Treatment | . | C85582 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 27 | 2020-03-27 | TSPARMCD | Paired | DCUTDESC | Data Cutoff Description | . | C98718 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 28 | 2020-03-27 | TSPARMCD | Paired | DCUTDTC | Data Cutoff Date | . | C98717 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 29 | 2020-03-27 | TSPARMCD | Paired | DGFCRIT | Delayed Graft Function Dx Criteria | . | C135514 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 30 | 2020-03-27 | TSPARMCD | Paired | DMCIND | Data Monitoring Committee Indicator | . | C127790 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 31 | 2020-03-27 | TSPARMCD | Paired | DOSE | Dose per Administration | . | C25488 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 32 | 2020-03-27 | TSPARMCD | Paired | DOSFRM | Dose Form | . | C42636 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 33 | 2020-03-27 | TSPARMCD | Paired | DOSFRQ | Dosing Frequency | . | C89081 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 34 | 2020-03-27 | TSPARMCD | Paired | DOSRGM | Dose Regimen | . | C71137 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 35 | 2020-03-27 | TSPARMCD | Paired | DOSU | Dose Units | . | C73558 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 36 | 2020-03-27 | TSPARMCD | Paired | DXCRIT | Diagnostic Criteria | . | C117960 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 37 | 2020-03-27 | TSPARMCD | Paired | EGBLIND | ECG Reading Blinded | . | C119560 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 38 | 2020-03-27 | TSPARMCD | Paired | EGCTMON | ECG Continuous Monitoring | . | C119561 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 39 | 2020-03-27 | TSPARMCD | Paired | EGLEADPR | ECG Planned Primary Lead | . | C119562 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 40 | 2020-03-27 | TSPARMCD | Paired | EGLEADSM | ECG Used Same Lead | . | C119563 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 41 | 2020-03-27 | TSPARMCD | Paired | EGRDMETH | ECG Read Method | . | C119564 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 42 | 2020-03-27 | TSPARMCD | Paired | EGREPLBL | ECG Replicates at Baseline | . | C119565 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 43 | 2020-03-27 | TSPARMCD | Paired | EGREPLTR | ECG Replicates On-Treatment | . | C119566 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 44 | 2020-03-27 | TSPARMCD | Paired | EGTWVALG | ECG Twave Algorithm | . | C119582 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 45 | 2020-03-27 | TSPARMCD | Paired | EMAILXML | Email Address for XML File | . | C127791 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 46 | 2020-03-27 | TSPARMCD | Paired | EMPIPDCN | EMA Decision Number for PIP | . | C126059 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 47 | 2020-03-27 | TSPARMCD | Paired | EURSBIND | EudraCT Resubmission Indicator | . | C126060 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 48 | 2020-03-27 | TSPARMCD | Paired | EVSNDID | EudraVigilance Sender ID | . | C126061 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 49 | 2020-03-27 | TSPARMCD | Paired | EVSNDORG | EudraVigilance Sender Organization | . | C126090 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 50 | 2020-03-27 | TSPARMCD | Paired | EXPARECN | Expanded Access Record NCT Number | . | C127792 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 51 | 2020-03-27 | TSPARMCD | Paired | EXPASTAT | Expanded Access Status | . | C127793 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 52 | 2020-03-27 | TSPARMCD | Paired | EXTTIND | Extension Trial Indicator | . | C139274 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 53 | 2020-03-27 | TSPARMCD | Paired | FCNTRY | Planned Country of Investigational Sites | . | C98770 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 54 | 2020-03-27 | TSPARMCD | Paired | FDADEIND | FDA-Regulated Device Study Indicator | . | C123629 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 55 | 2020-03-27 | TSPARMCD | Paired | FDADRIND | FDA-Regulated Drug Study Indicator | . | C123630 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 56 | 2020-03-27 | TSPARMCD | Paired | FDATCHSP | FDA Technical Specification | . | C156603 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 57 | 2020-03-27 | TSPARMCD | Paired | HLTSUBJI | Healthy Subject Indicator | . | C98737 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 58 | 2020-03-27 | TSPARMCD | Paired | INDIC | Trial Disease/Condition Indication | . | C112038 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 59 | 2020-03-27 | TSPARMCD | Paired | INTMODEL | Intervention Model | . | C98746 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 60 | 2020-03-27 | TSPARMCD | Paired | INTTYPE | Intervention Type | . | C98747 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 61 | 2020-03-27 | TSPARMCD | Paired | KEYWORD | Protocol Keyword | . | C126062 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 62 | 2020-03-27 | TSPARMCD | Paired | LENGTH | Trial Length | . | C49697 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 63 | 2020-03-27 | TSPARMCD | Paired | MNFCNTRY | Country of Manufacture | . | C124455 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 64 | 2020-03-27 | TSPARMCD | Paired | MSEUTIND | Multiple Site EU State Trial Indicator | . | C127794 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 65 | 2020-03-27 | TSPARMCD | Paired | NARMS | Planned Number of Arms | . | C98771 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 66 | 2020-03-27 | TSPARMCD | Paired | NCOHORT | Number of Groups/Cohorts | . | C126063 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 67 | 2020-03-27 | TSPARMCD | Paired | NUMSEUST | Number of Trial Sites EU State | . | C127795 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 68 | 2020-03-27 | TSPARMCD | Paired | OBJEXP | Trial Exploratory Objective | . | C163559 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 69 | 2020-03-27 | TSPARMCD | Paired | OBJPRIM | Trial Primary Objective | . | C85826 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 70 | 2020-03-27 | TSPARMCD | Paired | OBJSEC | Trial Secondary Objective | . | C85827 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 71 | 2020-03-27 | TSPARMCD | Paired | OBSMODEL | Observational Model | . | C126064 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 72 | 2020-03-27 | TSPARMCD | Paired | OBSTIMP | Observational Time Perspective | . | C126065 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 73 | 2020-03-27 | TSPARMCD | Paired | OBSTPOPD | Obs Study Population Description | . | C126066 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 74 | 2020-03-27 | TSPARMCD | Paired | OBSTSMM | Observational Study Sampling Method | . | C126067 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 75 | 2020-03-27 | TSPARMCD | Paired | OBSTSMMD | Obs Study Sampling Method Description | . | C126068 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 76 | 2020-03-27 | TSPARMCD | Paired | OUTMSADD | Additional Outcome Measure | . | C156601 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 77 | 2020-03-27 | TSPARMCD | Paired | OUTMSEXP | Exploratory Outcome Measure | . | C98724 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 78 | 2020-03-27 | TSPARMCD | Paired | OUTMSPRI | Primary Outcome Measure | . | C98772 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 79 | 2020-03-27 | TSPARMCD | Paired | OUTMSSEC | Secondary Outcome Measure | . | C98781 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 80 | 2020-03-27 | TSPARMCD | Paired | PASSIND | Post Authorization Safety Study Ind | . | C139275 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 81 | 2020-03-27 | TSPARMCD | Paired | PCLAS | Pharmacologic Class | . | C98768 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 82 | 2020-03-27 | TSPARMCD | Paired | PDPSTIND | Pediatric Postmarket Study Indicator | . | C123631 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 83 | 2020-03-27 | TSPARMCD | Paired | PDSTIND | Pediatric Study Indicator | . | C123632 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 84 | 2020-03-27 | TSPARMCD | Paired | PIPIND | Pediatric Investigation Plan Indicator | . | C126069 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 85 | 2020-03-27 | TSPARMCD | Paired | PLANSUB | Planned Number of Subjects | . | C49692 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 86 | 2020-03-27 | TSPARMCD | Paired | PLNTRDUR | Planned Trial Duration | . | C127796 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 87 | 2020-03-27 | TSPARMCD | Paired | PROTRSK | Protocol Risk Assessment | . | C139277 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 88 | 2020-03-27 | TSPARMCD | Paired | PTRTDUR | Planned Treatment Duration | . | C139276 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 89 | 2020-03-27 | TSPARMCD | Paired | PUBMEDID | PubMed ID for Citation Used in Study | . | C127797 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 90 | 2020-03-27 | TSPARMCD | Paired | RANDOM | Trial is Randomized | . | C25196 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 91 | 2020-03-27 | TSPARMCD | Paired | RANDQT | Randomization Quotient | . | C98775 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 92 | 2020-03-27 | TSPARMCD | Paired | RDIND | Rare Disease Indicator | . | C126070 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 93 | 2020-03-27 | TSPARMCD | Paired | REGID | Registry Identifier | . | C98714 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 94 | 2020-03-27 | TSPARMCD | Paired | RESUBLTR | Resubmission Letter | . | C126071 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 95 | 2020-03-27 | TSPARMCD | Paired | RLPSCRIT | Relapse Criteria | . | C117961 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 96 | 2020-03-27 | TSPARMCD | Paired | ROUTE | Route of Administration | . | C38114 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 97 | 2020-03-27 | TSPARMCD | Paired | RTSPCDES | Retained Biospecimen Description | . | C126072 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 98 | 2020-03-27 | TSPARMCD | Paired | RXMLCIND | Request for XML Copy of Study Indicator | . | C127798 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 99 | 2020-03-27 | TSPARMCD | Paired | SDMDUR | Stable Disease Minimum Duration | . | C98783 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 100 | 2020-03-27 | TSPARMCD | Paired | SDTIGVER | SDTM IG Version | . | C156604 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 101 | 2020-03-27 | TSPARMCD | Paired | SDTMVER | SDTM Version | . | C156605 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 102 | 2020-03-27 | TSPARMCD | Paired | SDXMLIND | Secure Delivery XML Required Indicator | . | C127799 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 103 | 2020-03-27 | TSPARMCD | Paired | SENDTC | Study End Date | . | C90462 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 104 | 2020-03-27 | TSPARMCD | Paired | SEVCRIT | Severity Criteria | . | C117962 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 105 | 2020-03-27 | TSPARMCD | Paired | SEXPOP | Sex of Participants | . | C49696 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 106 | 2020-03-27 | TSPARMCD | Paired | SPONSOR | Clinical Study Sponsor | . | C70793 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 107 | 2020-03-27 | TSPARMCD | Paired | SREVIND | SUSAR Reporting to EVCTM Indicator | . | C126073 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 108 | 2020-03-27 | TSPARMCD | Paired | SRNCAIND | SUSAR Reporting to NCA Indicator | . | C126074 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 109 | 2020-03-27 | TSPARMCD | Paired | SSEUTIND | Single Site EU State Trial Indicator | . | C127800 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 110 | 2020-03-27 | TSPARMCD | Paired | SSTDTC | Study Start Date | . | C69208 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 111 | 2020-03-27 | TSPARMCD | Paired | SSTDYDTL | Substudy Details | . | C126075 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 112 | 2020-03-27 | TSPARMCD | Paired | SSTDYIND | Substudy Planned Indicator | . | C126076 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 113 | 2020-03-27 | TSPARMCD | Paired | STOPRULE | Study Stop Rules | . | C49698 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 114 | 2020-03-27 | TSPARMCD | Paired | STRATFCT | Stratification Factor | . | C16153 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 115 | 2020-03-27 | TSPARMCD | Paired | STYPE | Study Type | . | C142175 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 116 | 2020-03-27 | TSPARMCD | Paired | TBLIND | Trial Blinding Schema | . | C49658 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 117 | 2020-03-27 | TSPARMCD | Paired | TCNTRL | Control Type | . | C49647 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 118 | 2020-03-27 | TSPARMCD | Paired | TDIGRP | Diagnosis Group | . | C49650 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 119 | 2020-03-27 | TSPARMCD | Paired | THERAREA | Therapeutic Area | . | C101302 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 120 | 2020-03-27 | TSPARMCD | Paired | TINDTP | Trial Intent Type | . | C49652 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 121 | 2020-03-27 | TSPARMCD | Paired | TITLE | Trial Title | . | C49802 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 122 | 2020-03-27 | TSPARMCD | Paired | TPHASE | Trial Phase Classification | . | C48281 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 123 | 2020-03-27 | TSPARMCD | Paired | TRGFUDUR | Target Follow-Up Duration | . | C126077 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 124 | 2020-03-27 | TSPARMCD | Paired | TRT | Investigational Therapy or Treatment | . | C41161 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 125 | 2020-03-27 | TSPARMCD | Paired | TTYPE | Trial Type | . | C49660 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 126 | 2020-03-27 | TSPARMCD | Paired | URLSTDY | URL Related to Study | . | C127801 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name | |||
| 127 | 2020-03-27 | TSPARMCD | Paired | URLSTDYD | URL Related to Study Description | . | C127802 | C66738 | C67152 | Yes | Yes | Trial Summary Parameter Test Code | TSPARM | Trial Summary Parameter Test Name |